sabatolimab
sabatolimab: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Novartis AG (NVS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Novartis AG (NVS) | Phase 2 |
Clinical Trials (1)
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Frequently asked questions
Who is developing sabatolimab?
sabatolimab is being developed by Novartis AG.
How many clinical trials involve sabatolimab?
BioSniper tracks 1 clinical trial involving sabatolimab.
Analyze Novartis AG & sabatolimab with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company